Kyte Group snaps up Ubitrade derivatives system

The Kyte Group, a London-based financial services group, has bought a futures and options back-office system from Ubitrade, a French trading and risk management software company.

Kyte has replaced its 10-year-old Atis back-office system with Ubitrade Futures & Options (Ubix) system to manage its listed derivatives activities.

Peter Green, Kyte's chief executive, said the company was seeking a system that could handle its large increase in transaction volumes while at the same time minimise operational risk. Ubix will enable Kyte to achieve T+0 straight-through processing and clearing internally, as well as externally with its brokers.

The Kyte Group is a diversified financial services group that encompasses Kyte Brokering and Kyte Fund Management. Kyte is active in financial futures, commodities, forex and options. Kyte is a clearing member of numerous exchanges globally, including Liffe, and is a non-clearing member of Euronext and Eurex.

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact info@risk.net or view our subscription options here: http://subscriptions.risk.net/subscribe

You are currently unable to copy this content. Please contact info@risk.net to find out more.

Chartis RiskTech100® 2024

The latest iteration of the Chartis RiskTech100®, a comprehensive independent study of the world’s major players in risk and compliance technology, is acknowledged as the go-to for clear, accurate analysis of the risk technology marketplace. With its…

T+1: complacency before the storm?

This paper, created by WatersTechnology in association with Gresham Technologies, outlines what the move to T+1 (next-day settlement) of broker/dealer-executed trades in the US and Canadian markets means for buy-side and sell-side firms

You need to sign in to use this feature. If you don’t have a Risk.net account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here